These results indicate that downregulation of Bcl-2 by AS Bcl-2 ODNs in breast cancer cells that normally overexpress Bcl-2 enhances their drug sensitivity, especially the sensitivity to DOX and taxanes. The gene discussed is BCL2; the disease is breast carcinoma.